ICT

ICT Module IV

Integrative Cancer Therapy Fellowship Module IV: Targeted Cancer Therapies

Upon completion of the module, the participant will:

  • Learn targeted therapies for acute myelogenous leukemia
  • Learn targeted therapies in breast and other female cancers
  • Know targeted treatments in chronic lymphocytic leukemia
  • Recognize targeted therapies in chronic myeloid leukemia
  • Know targeted therapies in colorectal and other GI cancers
  • Identify targeted therapies in non-small cell lung cancer
  • Comprehend targeted therapies in lymphoma
  • Know targeted treatment in melanoma
  • Identify targeted therapies in multiple myeloma
  • Know targeted treatments for myelodysplastic syndrome
  • Comprehend targeted therapies in epithelial ovarian cancer
  • Know targeted drug therapy in pancreatic cancer
  • Learn targeted therapy in prostate cancer
  • Comprehend targeted therapy in renal cell carcinoma
  • Learn targeted therapies in sarcoma
  • Learn about personalized cancer therapies
  • Learn about head and neck cancer treatments
  • Know brain cancer therapies
  • Comprehend new nanoparticle approaches to cancer
  • Explore genetic tissue testing
  • Discover the role proteomics has in cancer diagnosis and treatment

Schedule:

Personalizing cancer drug selection: pathology stains, genes and living cells Larry Wiesenthal, MD 4 hr
Cell signaling pathways, targeted agents and synergistic botanicals, implications for cancer treatment, with specific discussion of breast, lung, kidney and prostate cancer, myeloma, melanoma, and glioblastoma multiformae Dwight McKee, MD 6 hr
Cancer and Insulin Barry Boyd, MD 3 hr
Advances in Image Guided Cancer Ablation Jason Williams, MD 1 hr
3-BP Jason Williams, MD 1 hr
Immuno and Gene Therapy Jason Williams, MD 1 hr
Laetrile, Amygdalin and Cyanogenic Glycodsides in the Treatment of Cancer: Past, Present and Future Ralph Moss, PhD 3 hr
The Effects of Surgery on Tumor Growth: A Century of Investigations Mark Rosenberg, MD 1 hr
Evolutionary Dynamics of Cancer Robert Gillies, MD 3 hr
Glioblastoma Mark Rosenberg, MD 1 hr